News

This phase 2b study (ASPIRE) is currently underway.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

Several pharmaceutical companies have announced new appointments of executives and board members as they prepare for growth in 2025.

Wendy Lee, MD, an oculoplastics specialist and member of the program committee at EnVision Summit, shares an agenda that will include a mix of functional oculoplastics, aesthetics, and live facial rejuvenation demonstrations at the upcoming event, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

The clinical trial successfully met pre-specified visual acuity primary endpoints in both the US and European Union (EU)/United Kingdom (UK) with statistically significant near vision improvements recorded at all time points over 8 hours

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

The additions to the ANTERION Cornea App will be commercially available in February 2025

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

Clinicians need to better understand how to reduce the growth of antibiotic-resistant, more virulent bacteria, the authors said

Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October 2024.

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed.

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, and a dedicated webpage.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis

The collaboration between KIST and Huons BioPharma will span 14 months.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer.

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer

Most recently, Jacques served as Vice President of Healthcare Strategy, Partnerships & M&A at Microsoft.